Your browser doesn't support javascript.
loading
Rate and characteristics of inflammatory neuropathies associated with brentuximab vedotin therapy.
Matthys, Arthur; Bardel, Benjamin; Le Bras, Fabien; Créange, Alain; Nordine, Tarik; Gounot, Romain; Ingen-Housz-Oro, Saskia; Carvalho, Muriel; Lefaucheur, Jean-Pascal; Haioun, Corinne; Planté-Bordeneuve, Violaine; Gendre, Thierry.
Affiliation
  • Matthys A; Department of Neurology, AP-HP, Henri Mondor University Hospital, Créteil, France.
  • Bardel B; Center for Interdisciplinary Research in Biology, Collège de France, CNRS UMR 7241, INSERM U1050, Labex Memolife, PSL Research University, Paris, France.
  • Le Bras F; Unit of Clinical Neurophysiology, AP-HP, Henri Mondor University Hospital, Créteil, France.
  • Créange A; Reference Center for Neuromuscular Diseases Nord/Est/Ile-de-France, Paris, France.
  • Nordine T; Lymphoid Malignancies Unit, AP-HP, Henri Mondor University Hospital, Créteil, France.
  • Gounot R; Department of Neurology, AP-HP, Henri Mondor University Hospital, Créteil, France.
  • Ingen-Housz-Oro S; Reference Center for Neuromuscular Diseases Nord/Est/Ile-de-France, Paris, France.
  • Carvalho M; Unit of Clinical Neurophysiology, AP-HP, Henri Mondor University Hospital, Créteil, France.
  • Lefaucheur JP; Reference Center for Neuromuscular Diseases Nord/Est/Ile-de-France, Paris, France.
  • Haioun C; Lymphoid Malignancies Unit, AP-HP, Henri Mondor University Hospital, Créteil, France.
  • Planté-Bordeneuve V; Department of Dermatology, Paris-Est Créteil University EpiDermE, AP-HP, Henri Mondor University Hospital, Créteil, France.
  • Gendre T; Department of Pharmacy, AP-HP, Henri Mondor University Hospital, Créteil, France.
Eur J Neurol ; 31(7): e16285, 2024 Jul.
Article in En | MEDLINE | ID: mdl-38511878
ABSTRACT
BACKGROUND AND

PURPOSE:

Peripheral neuropathy is a frequent complication of brentuximab vedotin (BV), used in CD30+ lymphoma treatment. Classic BV-induced neuropathy (BV-CN) is a mild distal sensory axonal polyneuropathy. Severe BV-induced inflammatory neuropathies (BV-IN) have been described. BV-IN contribute to lymphoma-associated morbidity but might be immunotherapy-responsive. Our primary objective was to evaluate the rate of BV-IN. Our secondary objectives were to determine risk factors and warning signs.

METHODS:

We conducted a retrospective cohort study on all patients treated with BV at our center between April 2014 and September 2021. Clinical, biological, and electrophysiological data were collected. BV-induced neuropathy was defined as the occurrence of neuropathy up to 3 months after BV discontinuation. BV-IN was defined with criteria adapted from European Academy of Neurology/Peripheral Nerve Society 2021 electrodiagnostic criteria for chronic inflammatory demyelinating polyradiculoneuropathy. Other neuropathies were classified as BV-CN.

RESULTS:

Among 83 patients, 41 (49%) developed neuropathy 35 BV-CN and 6 BV-IN. Thus, the rate of BV-IN was 7.2%. Compared to patients with BV-CN, no predisposing factor was identified. However, patients with BV-IN more frequently presented muscle weakness (67% vs. 5.7%, p < 0.05), gait disorders (83% vs. 20%, p < 0.05), or acute or subacute onset (67% vs. 14%, p < 0.05). BV-IN was frequently more severe (Common Terminology Criteria for Adverse Events grade ≥3; 50% vs. 0%, p < 0.05). Four patients were treated with immunotherapy.

CONCLUSIONS:

Brentuximab vedotin-induced neuropathy is an overlooked complication. Based on four easily identifiable "red flags", we provide an algorithm to help non-neurologist physicians that care for BV-treated patients to detect BV-IN. The aim of the algorithm is to decrease the diagnostic and management delay of this disabling neuropathy.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Peripheral Nervous System Diseases / Antineoplastic Agents, Immunological / Brentuximab Vedotin Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Eur J Neurol Journal subject: NEUROLOGIA Year: 2024 Type: Article Affiliation country: France

Full text: 1 Database: MEDLINE Main subject: Peripheral Nervous System Diseases / Antineoplastic Agents, Immunological / Brentuximab Vedotin Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Eur J Neurol Journal subject: NEUROLOGIA Year: 2024 Type: Article Affiliation country: France